Dry Eye

Autologous Plasma Eye Drop

Singapore Eye Research Institute

Autologous Plasma Treatment for Severe Dry Eye Patients

Use of Autologous Plasma Eyedrops Therapy for Severe Dry Eye in Singapore

A Visual Analogue Scale (VAS) will be applied to evaluate dry eye symptoms as described by Schaumberg et al. (Schaumberg 2007). As shown in Appendix B , the scores will be recorded separately for frequency and severity of dry eye symptoms. The patient will be asked to check a point on a 100-mm line that corresponds to the degree of the symptom. The location of the mark made by the patient for each question will be measured in mm from the left hand side of the 100 mm line and recorded in mm. For the follow up visits, which measured the distance between the mark made by the patient and the central anchor, a negative value will be recorded if left of the anchor and a positive value if right of the anchor. The higher the number, implying more symptoms and frequency of experiencing dry eye.
A global score will be calculated by multiplying the frequency score by the severity score and taking the square root of the result (to transform back to the original scale).

Louis Tong

Clinician-Scientist, Senior Consultant

Singapore National Eye Centre

Health Science Authority Singapore

Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.

Abraxane Plus Cetuximab

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

To assess the overall response rate (complete and partial response) to Abraxane in patients with recurrent or metastatic head and neck cancer.

Overall Response Rate (Complete and Partial Response)

To assess the frequency and severity of toxicities associated with this treatment.

Frequency and Severity of Toxicities

Overall Survival and Progression-free Survival in Patients

Overall Study

Chao Family Comprehensive Cancer Center

Head and Neck Cancer

260 mg/m2 IV over 30 minutes every 3 weeks

Abraxane

Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles

Cetuximab

Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

A Phase II Study of Albumin Bound-Paclitaxel (AbraxaneTM) for Treatment of Recurrent or Metastatic Head and Neck Cancer With the Addition of Cetuximab (Erbitux) (IMC-225) on Disease Progression

keratitis/албумин

Autologous Plasma Treatment for Severe Dry Eye Patients

Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

Најкомплетната база на податоци за лековити билки поддржана од науката